aiqbench takeAI Products

This article details a clinical milestone where Science Corporation implanted its PRIMA chip to restore vision in a Stargardt disease patient, framing retinal prosthetics as a specific application of brain-computer interface technology. The core subject is the advancement of neural engineering and medical devices designed to interface directly with the nervous system to treat blindness, which falls squarely within the domain of applied machine learning and bio-integrated hardware.

Source coveringTechCrunch

What this isA model's reading of the article and related coverage, written for aiqbench. Not the publisher's words.

Science Corporation implants its vision-restoring chip in its first Stargardt disease patient

TechCrunchOctober 13, 20264 min read

Max Hodak, the former president and co-founder of Neuralink, detailed onstage at TechCrunch Disrupt how his company's work with PRIMA is part of its path toward a novel brain-computer interface (BCI).

Science Corporation CEO Max Hodak announced that the company has implanted its vision-restoring chip, PRIMA, into its first patient with Stargardt disease, an inherited eye disease that gradually destroys central vision. Hodak, the former president and co-founder of Neuralink, the brain implant company, explained on stage at TechCrunch Disrupt how the company’s work with PRIMA fits into its broader pursuit of a novel brain-computer interface (BCI). “The retina is part of the central nervous system,” Hodak said on stage. “We consider cochlear implants, retinal…

Excerpt shown under the publisher's RSS terms · 84 words · full text and figures are on the publisher's site

Read at TechCrunch ↗Ask about this article